(2023)
Statin use and the risk of hepatocellular carcinoma among patients with chronic hepatitis B: an emulated target trial using longitudinal nationwide population cohort data.
BMC GASTROENTEROLOGY.
23,
1
(2023)
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
JHEP REPORTS.
5,
9
(2023)
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study.
PLOS ONE.
18,
7
(2023)
Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY.
21,
7
(2023)
Effect of lifestyle modification on hepatocellular carcinoma incidence and mortality among patients with chronic hepatitis B.
WORLD JOURNAL OF GASTROENTEROLOGY.
29,
24
(2023)
Improved on-treatment fibrosis-4 during antiviral therapy and lower hepatocellular carcinoma risk in cirrhotic patients with hepatitis B.
SCIENTIFIC REPORTS.
13,
1
(2023)
Associations of physical activity domains and muscle strength exercise with non-alcoholic fatty liver disease: a nation-wide cohort study.
SCIENTIFIC REPORTS.
13,
1
(2022)
Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea.
KOREAN JOURNAL OF INTERNAL MEDICINE.
37,
5
(2022)
Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
DIGESTIVE DISEASES AND SCIENCES.
67,
9
(2022)
Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.
FRONTIERS IN ONCOLOGY.
12,
-
(2022)
Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy.
SCIENTIFIC REPORTS.
12,
1
(2022)
Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study.
BMC MEDICINE.
20,
1
(2022)
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
GENOME MEDICINE.
14,
1
(2022)
Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY.
34,
1
(2022)
Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY.
57,
1
(2021)
The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.
HEPATOLOGY.
74,
6
(2021)
Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY.
33,
1S suppl 1
(2021)
Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
JOURNAL OF VIRAL HEPATITIS.
28,
10
(2021)
Inclusive Quantification Assay of Serum Des-gamma-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry.
HEPATOLOGY COMMUNICATIONS.
5,
10
(2021)
Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
PLOS ONE.
16,
8
학술회의논문
(2104)
Effect of HBV reactivation on the recurrence of hepatitis B-related hepatocellular carcinoma after curative resection in patients with low viral load.
The liver week 2014.
대한민국
(2017)
Clinical Characteristics, Potencial Etiology and Mode of Detection for Non-B Non-C Hepatocellular Carcinoma in Korea.
KDDW 2017.
대한민국
(2017)
Comparison of Treatment Efficacy between Entecavir (ETV) and Tenofovir Disoproxil Fumarate (TDF) in Treatment-naive Chronic Hepatitis B Patients: Long-term Real-world Experience.
KDDW 2017.
대한민국
(2015)
Dynamic change of nonalcoholic fatty liver disease and therisk of carotid atherosclerosis.
대한소화기학회.
대한민국
(2015)
Locoregional therapy or liver transplantation forhepatocellular carcinoma fulfilling the Milan criteria.
대한소화기학회.
대한민국
(2015)
Discontinuation of Antiviral prophylaxis in Hepatitis B Virus Infected Patients Who Received Cytotoxic Chemotherapy: Outcomes and Predictors.
AASLD.
미국
(2015)
Promotion of Hepatocarcinogenesis by the Endocannabinoid Anandamide and its Receptor CB1.
AASLD.
미국
(2015)
Survival of hepatocellular carcinoma patients according to recommended treatment by the Barcelona Clinic Liver Cancer or Hong Kong Liver Cancer staging system in hepatitis B endemic area.
AASLD.
미국
(2015)
Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels..
AASLD.
미국
(2015)
Lamivudine vs. Entecavir for the newly diagnosed hepatitis B-virus related Hepatocellular carcinoma.
AASLD.
미국
(2015)
Long term outcome after resection of intermediate hepatocellular carcinoma: comparison to transarterial chemoembolization.
AASLD.
미국
(2015)
Survival and prognostic factors in patients with intermediate stage hepatocellular carcinoma (HCC) who were treated with repeated transarterial chemoembolization (TACE).
AASLD.
미국
(2015)
Cause of death in patients with hepatocellular carcinoma within the Milan criteria.
대한간암학회.
대한민국
(2015)
Combined Radiation Therapy (RT) and Hyperthermia after Trans-catheter Arterial Chemoembolization for Hrpatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT) : Prospective Phase 2 Trial.
대한간암학회.
대한민국
(2015)
Effect of Oral Antiviral Treatment on Long-Term Outcomes of Radiofrequency Ablation Therapy for Hepatitis B Virus-Related Hepatocellular Carcinoma.
대한간암학회.
대한민국
(2015)
Hepatocellular Carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low trial load.
대한간암학회.
대한민국
(2014)
Effect of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load.
AASLD.
미국
(2014)
HBV DNA / Quantitative HBsAg level ratio, but not either quantitative HBsAg level or HBV DNA, can predict hepatocellular carcinoma development in HBsAg-nagative chronic hepatitis patients with HBV DNA ≥2000 IU/ml.
AAASLD.
미국
(2014)
Risk of development of hepatocellular carcinoma in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferse levels.
AASLD.
미국
(2014)
The importance of intrahepatic tumor in hepatocellular carcinoma with extrahepatic spread in patients treated with sorafenib.
AASLD.
미국
